LPA and atherosclerosis: Olpasiran is currently being evaluated in the double-blind, randomized, placebo-controlled phase 3 OCEAN(a)-Outcomes trial (NCT05581303) enrolling ASCVD patients with baseline Lp(a) levels ≥200 nmol/L [51].